Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in ...
Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...